title: Quantitative analysis of mRNA expression of TIMPs in the periprosthetic interface tissue of loose hips by real-time PCR system.
abstract: Matrix metalloproteinases (MMPs) and their endogenous inhibitors, tissue inhibitors of metalloproteinases (TIMPs), have been reported to play a critical role in extracellular degradation around artificial hip joints. Although messenger ribonucleic acid (mRNA) expression patterns of several MMPs and TIMPs were reported, there is no report of quantitative mRNA analysis of TIMPs in periprosthetic tissues. In this study, mRNA expression of four different types of TIMPs in periprosthetic interface tissue of loose hips was analyzed by a quantitative polymerase chain reaction system. The mRNA expression level of TIMP-1, -2, and -3 in periprosthetic interface tissue was significantly higher than that in control. In contrast, the mRNA expression level of TIMP-4 in the periprosthetic interface tissue was lower. This study suggested that increased levels of TIMP-1, -2, and -3, and decreased levels of TIMP-4 may contribute to pathologic extracellular matrix degradation in combination with MMPs, thus leading to prosthetic loosening and osteolysis around artificial total hip joints.
authors.affiliation: Department of Orthopaedic Surgery, Yamagata University School of Medicine, Yamagata, 990-9585, Japan. s-kan@msb.biglobe.ne.jp
authors.forename: K
authors.initials: K
authors.lastname: Sasaki
authors.forename: M
authors.initials: M
authors.lastname: Takagi
authors.forename: J
authors.initials: J
authors.lastname: Mandelin
authors.forename: I
authors.initials: I
authors.lastname: Takei
authors.forename: S
authors.initials: S
authors.lastname: Santavirta
authors.forename: H
authors.initials: H
authors.lastname: Ida
authors.forename: T
authors.initials: T
authors.lastname: Ogino
authors.forename: Y T
authors.initials: YT
authors.lastname: Konttinen
mesh_terms: D000368:Aged; D003199:Computer Systems; D003238:Connective Tissue / Q000378:metabolism*; D003843:Deoxycytidine Monophosphate / Q000031:analogs & derivatives; D054306:Dideoxynucleotides; D004789:Enzyme Activation; D019544:Equipment Failure Analysis; D016326:Extracellular Matrix Proteins / Q000378:metabolism; D005260:Female; D006622:Hip Prosthesis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010014:Osteolysis / Q000235:genetics / Q000378:metabolism*; D016133:Polymerase Chain Reaction / Q000379:methods*; D011475:Prosthesis Failure; D012333:RNA, Messenger / Q000096:biosynthesis* / Q000235:genetics; D013873:Thionucleotides; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000096:biosynthesis / Q000235:genetics; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000096:biosynthesis / Q000235:genetics; D019717:Tissue Inhibitor of Metalloproteinase-3 / Q000096:biosynthesis / Q000235:genetics; D019714:Tissue Inhibitor of Metalloproteinases / Q000096:biosynthesis* / Q000235:genetics; D000097792:Tissue Inhibitor of Metalloproteinase-4
chemical_list: D003843:Deoxycytidine Monophosphate; D054306:Dideoxynucleotides; D016326:Extracellular Matrix Proteins; D012333:RNA, Messenger; D013873:Thionucleotides; D019715:Tissue Inhibitor of Metalloproteinase-1; D019716:Tissue Inhibitor of Metalloproteinase-2; D019717:Tissue Inhibitor of Metalloproteinase-3; D019714:Tissue Inhibitor of Metalloproteinases; D000097792:Tissue Inhibitor of Metalloproteinase-4; C117033:D4T-5'-(p-bromophenyl methoxyalaninyl phosphate)